Baricitinib Production Cost Reports

The report provides a detailed analysis essential for establishing a Baricitinib manufacturing plant. It encompasses all critical aspects necessary for Baricitinib production, including the cost of Baricitinib production, Baricitinib plant cost, Baricitinib production costs, and the overall Baricitinib manufacturing plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a Baricitinib production plant. These encompass manufacturing processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Baricitinib is an inhibitor of Janus kinase used to treat moderate-to-severe rheumatoid arthritis. It is a member of the class of drugs called disease-modifying antirheumatic drugs (DMARDs) and inhibits JAK1 and JAK2 activity, which reduces JAK-mediated immune responses and inflammation. Adult patients with moderately to severely active rheumatoid arthritis who have not responded well to one or more TNF blockers may benefit from treatment with Baricitinib.

The procurement of Baricitinib is influenced by its application in the pharmaceutical and medical industries to treat moderate-to-severe rheumatoid arthritis. The demand for Baricitinib is also increasing due to the rising cases of rheumatoid arthritis. The majority of demand comes from the aging population since they have a higher chance of acquiring rheumatoid arthritis. It is recommended for the management of moderate-to-severe atopic dermatitis in adult patients who are suitable for systemic therapy. It is also recommended for the treatment of coronavirus disease 2019 (COVID-19) and has recently been approved as a therapy for adult patients with severe alopecia areata.

Baricitinib can be taken either on its own or in conjunction with other DMARDs, such as methotrexate, which increases its demand. In general, the industrial Baricitinib procurement directly depends on its usage in the pharmaceutical and medical industries, rising cases of rheumatoid arthritis, the aging population, usage with other DMARDs, its wide range of applications, increasing healthcare awareness among people, cost-efficiency, rising technological advancements, research & development, and regulatory approvals.

Raw Material for Baricitinib Production

According to the Baricitinib manufacturing plant project report, the key raw material used in the production of Baricitinib includes 1-Boc-3-azetidinone.

Manufacturing Process of Baricitinib

The extensive Baricitinib production cost report consists of the following major industrial manufacturing process:

• Production from 1-Boc-3-azetidinone: The manufacturing process of Baricitinib involves several steps. Firstly, the starting compound undergoes the Horner–Emmons reaction in the presence of NaH as the base to form the first intermediate. The next step is deprotection in the presence of trifluoroacetic acid (TFA) to produce another intermediate. The intermediate is subjected to a sulfonamidation reaction with ethanesulfonylchloride to form another intermediate, which then undergoes nucleophilic substitution reaction with 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole to form the final intermediate. The final step is the Suzuki coupling reaction between the intermediate and 4-chloro-7H-pyrrolo[2,3-d]pyrimidine in the presence of Pd(PPh3)4, CsF, t-BuOH, H2O, and toluene to produce Baricitinib.

Baricitinib, commercially known as Olumiant, is a white to off-white powder, having the molecular formula C16H17N7O2S and a molecular weight of 371.4 g/mol. It has a boiling point of around 707.2 °C. It has a water solubility of 0.357 mg/mL. The value of its log P is 1.08. The value of its dissociation constant, pKa, is 13.89. It is a pyrrolopyrimidine, a sulfonamide, a nitrile, a member of the pyrazoles, and a member of the azetidines. It is an inhibitor of Janus kinase inhibitor used to treat moderate-to-severe rheumatoid arthritis.